| Literature DB >> 34727689 |
Muthuraj Prakash1, Yukihiro Itoh1,2, Yoshie Fujiwara3, Yukari Takahashi1, Yuri Takada2, Paolo Mellini1, Elghareeb E Elboray1,4, Mitsuhiro Terao2, Yasunobu Yamashita2, Chika Yamamoto5, Takao Yamaguchi5, Masayuki Kotoku1, Yuki Kitao1, Ritesh Singh1,6, Rohini Roy3,7, Satoshi Obika5, Makoto Oba1, Dan Ohtan Wang3,8,9, Takayoshi Suzuki1,2,10.
Abstract
Fat mass obesity-associated protein (FTO) is a DNA/RNA demethylase involved in the epigenetic regulation of various genes and is considered a therapeutic target for obesity, cancer, and neurological disorders. Here, we aimed to design novel FTO-selective inhibitors by merging fragments of previously reported FTO inhibitors. Among the synthesized analogues, compound 11b, which merges key fragments of Hz (3) and MA (4), inhibited FTO selectively over alkylation repair homologue 5 (ALKBH5), another DNA/RNA demethylase. Treatment of acute monocytic leukemia NOMO-1 cells with a prodrug of 11b decreased the viability of acute monocytic leukemia cells, increased the level of the FTO substrate N6-methyladenosine in mRNA, and induced upregulation of MYC and downregulation of RARA, which are FTO target genes. Thus, Hz (3)/MA (4) hybrid analogues represent an entry into a new class of FTO-selective inhibitors.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34727689 DOI: 10.1021/acs.jmedchem.1c01107
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446